Literature DB >> 20121730

Recipient dendritic cells, but not B cells, are required antigen-presenting cells for peripheral alloreactive CD8+ T-cell tolerance.

J L Mollov1, C L Lucas1, F Haspot1, J Kurtz C Gaspar1, A Guzman1, M Sykes1.   

Abstract

Induction of mixed allogeneic chimerism is a promising approach for achieving donor-specific tolerance, thereby obviating the need for life-long immunosuppression for solid organ allograft acceptance. In mice receiving a low dose (3Gy) of total body irradiation, allogeneic bone marrow transplantation combined with anti-CD154 tolerizes peripheral CD4 and CD8 T cells, allowing achievement of mixed chimerism with specific tolerance to donor. With this approach, peripheral CD8 T-cell tolerance requires recipient MHC class II, CD4 T cells, B cells and DCs. Recipient-type B cells from chimeras that were tolerant to donor still promoted CD8 T-cell tolerance, but their role could not be replaced by donor-type B cells. Using recipients whose B cells or DCs specifically lack MHC class I and/or class II or lack CD80 and CD86, we demonstrate that dendritic cells (DCs) must express CD80/86 and either MHC class I or class II to promote CD8 tolerance. In contrast, B cells, though required, did not need to express MHC class I or class II or CD80/86 to promote CD8 tolerance. Moreover, recipient IDO and IL-10 were not required. Thus, antigen presentation by recipient DCs and not by B cells is critical for peripheral alloreactive CD8 T cell tolerance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20121730      PMCID: PMC4215806          DOI: 10.1111/j.1600-6143.2009.02967.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  31 in total

1.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.

Authors:  T Kawai; D Andrews; R B Colvin; D H Sachs; A B Cosimi
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  B-cell suppression of delayed hypersensitivity reactions.

Authors:  S I Katz; D Parker; J L Turk
Journal:  Nature       Date:  1974-10-11       Impact factor: 49.962

3.  Establishment of monoclonal anti-Nk-1.1 antibody.

Authors:  G C Koo; J R Peppard
Journal:  Hybridoma       Date:  1984

4.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

5.  B cells regulate autoimmunity by provision of IL-10.

Authors:  Simon Fillatreau; Claire H Sweenie; Mandy J McGeachy; David Gray; Stephen M Anderton
Journal:  Nat Immunol       Date:  2002-09-03       Impact factor: 25.606

6.  Earlier low-dose TBI or DST overcomes CD8+ T-cell-mediated alloresistance to allogeneic marrow in recipients of anti-CD40L.

Authors:  Yasuo Takeuchi; Hiroshi Ito; Josef Kurtz; Thomas Wekerle; Leon Ho; Megan Sykes
Journal:  Am J Transplant       Date:  2004-01       Impact factor: 8.086

Review 7.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

8.  CTLA-4-Ig regulates tryptophan catabolism in vivo.

Authors:  Ursula Grohmann; Ciriana Orabona; Francesca Fallarino; Carmine Vacca; Filippo Calcinaro; Alberto Falorni; Paola Candeloro; Maria L Belladonna; Roberta Bianchi; Maria C Fioretti; Paolo Puccetti
Journal:  Nat Immunol       Date:  2002-09-30       Impact factor: 25.606

9.  B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1.

Authors:  Vrajesh V Parekh; Durbaka V R Prasad; Pinaki P Banerjee; Bimba N Joshi; Anil Kumar; Gyan C Mishra
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

10.  Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.

Authors:  David H Munn; Madhav D Sharma; Andrew L Mellor
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

View more
  10 in total

1.  Layers of regulation in induction of mixed chimerism by anti-CD40L.

Authors:  Carrie L Lucas; Megan Sykes
Journal:  Chimerism       Date:  2011 Oct-Dec

Review 2.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

Review 3.  Induction of tolerance through mixed chimerism.

Authors:  David H Sachs; Tatsuo Kawai; Megan Sykes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

4.  LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.

Authors:  Carrie L Lucas; Creg J Workman; Semir Beyaz; Samuel LoCascio; Guiling Zhao; Dario A A Vignali; Megan Sykes
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

Review 5.  Hematopoietic stem cell infusion/transplantation for induction of allograft tolerance.

Authors:  Jose M M Granados; Gilles Benichou; Tatsuo Kawai
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

Review 6.  Mechanisms of Mixed Chimerism-Based Transplant Tolerance.

Authors:  Julien Zuber; Megan Sykes
Journal:  Trends Immunol       Date:  2017-08-18       Impact factor: 16.687

Review 7.  Experimental models of B cell tolerance in transplantation.

Authors:  Michelle L Cowan; Roger Sciammas; Anita S Chong
Journal:  Semin Immunol       Date:  2011-09-16       Impact factor: 11.130

Review 8.  Immune monitoring of transplant patients in transient mixed chimerism tolerance trials.

Authors:  Megan Sykes
Journal:  Hum Immunol       Date:  2017-12-28       Impact factor: 2.850

Review 9.  Transplantation tolerance and its outcome during infections and inflammation.

Authors:  Anita S Chong; Maria-Luisa Alegre
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

10.  Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy.

Authors:  Ulrike Baranyi; Andreas M Farkas; Karin Hock; Benedikt Mahr; Birgit Linhart; Martina Gattringer; Margit Focke-Tejkl; Arnd Petersen; Fritz Wrba; Thomas Rülicke; Rudolf Valenta; Thomas Wekerle
Journal:  EBioMedicine       Date:  2016-03-20       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.